ClinicalTrialsFinder
RecruitingPhase 4NCT07224529

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

Sponsor

University of Alabama at Birmingham

Enrollment

48 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Meibomian Gland Dysfunction (MGD)

Summary

This research study evaluates a prescription eye drop called Vevye® (cyclosporine 0.1%) for adults who have meibomian gland dysfunction (MGD), a common eye condition that can cause dry, irritated, or burning eyes. If you join the study, after a short "run-in" period using artificial tears, you will receive Vevye twice a day for about 24 weeks (approximately six months). During that time you will attend several clinic visits where your eye symptoms, lid health, tear film, and meibomian gland function will be assessed. The goal is to learn whether Vevye improves symptoms (like eye dryness or irritation) and signs (such as changes on the eye's surface or lid margins) of MGD. You will also be monitored for safety and comfort of the eye drop. The information obtained from this study may help determine whether this treatment is beneficial for people with this condition and contribute to future care options. Participation is voluntary and you may stop at any time.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age > 18 years
  • VAS Dryness > 70
  • Posterior lid margin hyperemia grade 2 or worse for both eyes
  • Corneal fluorescein staining > 6 (NEI scale) for at least one eye
  • Modified meibomian gland expression score ≥ 23 for both eyes OR ≥ 7 for expressible glands for both eyes OR a combination of the two
  • Unanesthetized Schirmer ≥ 5 mm in 5 minutes for both eyes

Exclusion Criteria42

  • Age > 18 years
  • VAS Dryness > 70
  • Posterior lid margin hyperemia grade 2 or worse for both eyes
  • Corneal fluorescein staining > 6 (NEI scale) for at least one eye
  • Modified meibomian gland expression score ≥ 23 for both eyes OR ≥ 7 for expressible glands for both eyes OR a combination of the two
  • Unanesthetized Schirmer ≥ 5 mm in 5 minutes for both eyes
  • Contact lens wear within two weeks of study enrollment or planned during study period
  • Habitual visual acuity worse than 0.30 logMAR in either eye
  • Previous or current diagnosis of any of the following conditions:
  • Sjögren's disease
  • Stevens-Johnson syndrome
  • Keratoconus
  • Herpetic keratitis
  • Pterygium
  • Any other condition that in the opinion of the clinician would interfere with study parameters
  • Use of any of the following medications within 30 days of enrollment:
  • Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)
  • Xiidra®
  • Miebo®
  • Tyrvaya
  • Tryptyr®
  • Topical ocular steroids
  • Any topical anti-glaucoma medication
  • Any of the following procedural treatments for MGD within 6 months of enrollment:
  • LipiFlow®
  • TearCare®
  • iLux®
  • Intense pulsed light (IPL)
  • Therapeutic gland expression
  • Any other procedure targeting the meibomian glands
  • Insertion or removal of permanent punctal plugs within 3 months of enrollment
  • Insertion of dissolvable punctal plugs within 9 months of enrollment (or within 3 months of expected dissolution date, if known)
  • Presence of active ocular allergies
  • Previous intraocular surgery within 6 months of enrollment
  • Previous refractive surgery within 2 years of enrollment
  • Current or planned pregnancy during the study period
  • Current or planned lactation during the study period
  • Females of childbearing potential who are not using effective contraception
  • Known allergy or sensitivity to the study drug
  • Dose modification of oral antihistamines or antidepressants within 1 month of enrollment
  • Current enrollment or enrollment within 60 days in any other study of an investigational drug or device
  • Clinical opinion of the study doctor based on clinical examination and/or participant compliance with protocol requirements

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVevye(Cyclosporine 0.1% Ophthalmic Solution)

Participants will administer Vevye® (cyclosporine 0.1% ophthalmic solution) twice daily in both eyes for 24 weeks following a 2-week run-in period using a commercially available artificial tear. Vevye® contains cyclosporine, a calcineurin inhibitor that reduces ocular surface inflammation, dissolved in a semifluorinated alkane vehicle (perfluorobutylpentane, F4H5), which is preservative-free, water-free, and has no associated pH or osmolarity. The formulation is designed to enhance tear stability and reduce inflammatory processes associated with meibomian gland dysfunction (MGD). All participants receive the same treatment in this non-randomized, open-label, single-group interventional trial evaluating the efficacy and safety of Vevye® for MGD.

Locations(1)

University of Alabama at Birmingham, School of Optometry, Clinical Eye Research Facility

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07224529